Climb Bio, Inc. (CLYM)
10.78
-0.16
(-1.46%)
USD |
NASDAQ |
Oct 05, 09:54
Climb Bio 1 Year Total Returns (Daily) : 436.3% for Oct. 2, 2026
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| October 02, 2026 | 436.3% |
| October 01, 2026 | 461.9% |
| September 30, 2026 | 470.6% |
| September 29, 2026 | 477.9% |
| September 28, 2026 | 451.2% |
| September 25, 2026 | 455.2% |
| September 24, 2026 | 442.9% |
| September 23, 2026 | 456.4% |
| September 22, 2026 | 512.5% |
| September 21, 2026 | 490.5% |
| September 18, 2026 | 527.2% |
| September 17, 2026 | 563.2% |
| September 16, 2026 | 602.0% |
| September 15, 2026 | 581.9% |
| September 14, 2026 | 547.1% |
| September 11, 2026 | 493.8% |
| September 10, 2026 | 528.2% |
| September 09, 2026 | 532.4% |
| September 08, 2026 | 543.7% |
| September 04, 2026 | 566.1% |
| September 03, 2026 | 498.0% |
| September 02, 2026 | 574.9% |
| September 01, 2026 | 564.6% |
| August 31, 2026 | 515.7% |
| August 28, 2026 | 533.5% |
| Date | Value |
|---|---|
| August 27, 2026 | 559.1% |
| August 26, 2026 | 590.1% |
| August 25, 2026 | 619.4% |
| August 24, 2026 | 589.1% |
| August 21, 2026 | 689.0% |
| August 20, 2026 | 656.4% |
| August 19, 2026 | 758.4% |
| August 18, 2026 | 724.2% |
| August 17, 2026 | 817.9% |
| August 14, 2026 | 849.4% |
| August 13, 2026 | 803.7% |
| August 12, 2026 | 793.8% |
| August 11, 2026 | 739.4% |
| August 10, 2026 | 696.5% |
| August 07, 2026 | 733.3% |
| August 06, 2026 | 700.0% |
| August 05, 2026 | 616.7% |
| August 04, 2026 | 638.8% |
| August 03, 2026 | 714.5% |
| July 31, 2026 | 750.0% |
| July 30, 2026 | 694.7% |
| July 29, 2026 | 702.0% |
| July 28, 2026 | 668.1% |
| July 27, 2026 | 782.1% |
| July 24, 2026 | 767.6% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Korsana Biosciences, Inc. | 75.63% |
| Cullinan Therapeutics, Inc. | 169.7% |
| Q32 Bio, Inc. | 297.6% |
| Artiva Biotherapeutics, Inc. | 131.5% |
| Arrowhead Pharmaceuticals, Inc. | 85.52% |